New chemotherapy approaches in colorectal cancer

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 275-286

  Grothey, Axel ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PEMETREXED; RALTITREXED; TEGAFUR; TRIMETREXATE; URACIL;

CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG CYTOTOXICITY; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; PALLIATIVE CARE; SURVIVAL RATE;

EID: 0034955033     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00011     Document Type: Review

References (71)

1. Cancer statistics, 2000
2. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
3. New drugs in the treatment of colorectal carcinoma
4. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
5. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
6. Infusional 5-FU: Historical evolution, rationale, and clinical experience
7. Multicenter phase III study of 5-fluorouracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer
8. Randomized comparative study of ORZEL (oral uracil/tegafur (UFTTM) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
9. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer
10. Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma
11. UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer
12. UFT plus calcium folinate/irinotecan in colorectal cancer
13. UFT/leucovorin vs 5-FU/leucovorin in colon cancer
14. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
15. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
16. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
17. A phase III trial of XELODA TM (capecitabine) in previously untreated advanced/metastatic colorectal cancer
18. A phase III trial (S014796) of XelodaTM (capecitabine) in previously untreated advanced/metastatic colorectal cancer
19. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
20. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
21. Phase I study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors
22. Eniluracil: An irreversible inhibitor of dihydropyrimidine dehydrogenase
23. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
24. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
25. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma
26. Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer
27. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
28. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer: Results of a randomized, multicenter, North American trial
29. Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
30. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06
31. Mature results from three large controlled studies with raltitrexed ("Tomudex")
32. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ("Tomudex")
33. Chemotherapy in elderly patients with colorectal cancer
34. Tomudex (raltitrexed) in elderly patients with advanced colorectal cancer (ACC): An effective palliative treatment
35. Promising therapeutic potential of oxaliplatin + raltitrexed in patients with advanced colorectal cancer (ACC): Results of a phase I/II trial
36. Raltitrexed ("Tomudex") plus oxaliplatin: An active combination for first-line chemotherapy in patients with metastatic colorectal cancer
37. Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors
38. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
39. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
40. A phase I study of the multitargeted antifolate ALIMTA in combination with oxaliplatin (LOHP) in metastatic solid tumors
41. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
42. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
43. Irinotecan in the treatment of colorectal cancer: Clinical overview
44. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
45. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
46. Bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo Clinic) versus weekly, high-dose 24h 5-FU-infusion + FA plus oxaliplatin (LOHP) in advanced colorectal cancer (CRC)
47. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer [correspondence]
48. FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Preliminary results of a randomized phase III study of the GERCOR
49. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy
50. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
51. Hepatic resection for metastases from colorectal carcinoma: A survival analysis
52. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients
53. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older
54. Hepatic artery chemoembolization (CE) with irinotecan (I) for primary and metastatic liver cancer: Preliminary results
55. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer
56. Adjuvant therapy for patients with colon and rectal cancer
57. Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer
58. Adjuvant chemotherapy for colon cancer (CC) is beneficiai without significantly increased toxicity in elderly patients (pts): Results from a 3351 pt meta-analysis
59. New directions in the treatment of colorectal cancer: A look to the future
60. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5 fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
61. A phase I/II study of SU5416 in combination with 5-fu/leucovorin in patients with metastatic colorectal cancer
62. Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma
63. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts
64. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
65. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
66. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients (pts) with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens
67. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
68. ZD1839 ("Iressa") as an anticancer agent
69. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
70. Responsiveness of metastatic colorectal cancers to chemotherapy with CPT11
71. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status